Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Clinical Genitourinary Cancer
|
March 19, 2018
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents
Antoine Angelergues, Eleni Efstathiou, Revekka Gyftaki, et al.
Communications Medicine
|
April 24, 2025
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma
David Tougeron, Christophe Louvet, Jérôme Desramé, et al.
Nature Communications
|
July 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, et al.
Nature Communications
|
January 6, 2026
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial
Isabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma, et al.
JAMA Oncology
|
April 4, 2024
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial
David Tougeron, Laetitia Dahan, Ludovic Evesque, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2024
Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort
David Tougeron, Frederic Bibeau, Benoist Chibaudel, et al.
Lancet (London, England)
|
December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
The New England Journal of Medicine
|
December 6, 2023
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
Kathleen N Moore, Antoine Angelergues, Gottfried E Konecny, et al.
The New England Journal of Medicine
|
July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Ignace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Clinical Genitourinary Cancer
|
March 19, 2018
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents
Antoine Angelergues, Eleni Efstathiou, Revekka Gyftaki, et al.
Communications Medicine
|
April 24, 2025
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma
David Tougeron, Christophe Louvet, Jérôme Desramé, et al.
Nature Communications
|
July 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, et al.
Nature Communications
|
January 6, 2026
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial
Isabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma, et al.
JAMA Oncology
|
April 4, 2024
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial
David Tougeron, Laetitia Dahan, Ludovic Evesque, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 1, 2024
Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort
David Tougeron, Frederic Bibeau, Benoist Chibaudel, et al.
Lancet (London, England)
|
December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
The New England Journal of Medicine
|
December 6, 2023
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
Kathleen N Moore, Antoine Angelergues, Gottfried E Konecny, et al.
The New England Journal of Medicine
|
July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Ignace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.
Page
of 2